Search for content, post, videos

BerGenBio establish Oncology Scientific Advisory Board

BerGenBio has announced the formation of a scientific advisory board consisting of four non-small cell lung cancer (NSCLC) experts from top oncology centers around the globe to enhance the development of bemcentinib for the treatment of NSCLC patients with STK11 mutations. “We are very proud an
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.